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The biopiracy debacle – Can India protect her traditional knowledge? 
 
In the last decade and at the turn of the new millennium, we witnessed India’s successful 
campaign against wrong patents granted in the US for which “prior art” (evidence of prior use) 
existed in the codified literature of India’s medical traditions. 
 
The patents of turmeric for wound healing and neem for anti fungal properties were revoked 
after a battle that lasted for two and five years respectively.  These crusades proved that it was 
possible to reverse wrongly granted patents at the international level but also that such efforts are 
time consuming and expensive. 
 
Patent laws vary from country to country but generally, everyone follows a system wherein a 
patent application is rejected if there is a prior art or previously existing knowledge regarding the 
application of a particular product.  It is important to realize that the definition of prior art also 
varies across countries. In the US for example, previous known use within the country is prior 
art, but not when the knowledge comes from outside the country, unless it is documented or 
patented.  In effect, US patent law does not recognize undocumented knowledge outside the US 
as prior art.  Thus, to protect traditional medical knowledge of India from the US patent system, 
we have to ensure two things – 1.Comprehensive documentation and 2. Filing patents through 
scientific research on traditional medical knowledge.  
 
Even when a country recognizes undocumented use as prior art or documented use for that 
matter, such knowledge must be accessible to the patent office to prevent a patent from being 
granted.  Most often, this is not the case and so patents can always be granted wrongly and then 
one will have to engage in the time consuming and expensive exercise to revoke it.  It was found 
that out of 5000 patent granted by the US patents office; about 80% were based on plants of 
Indian origin. 
 
A country like India has a rich knowledge base of traditional medicine both in documented 
(textual traditions) and undocumented (oral tradition) forms.  A significant number of the texts 
are in the public domain but a large chunk is stored in public and private repositories as palm leaf 
or paper inscriptions and has not yet been published.  Out of the published texts, several have 
been translated into English and mainly other Indian languages. Suffice it to say that a big 
percentage of the literature on the codified version of the Indian medical literature remains 
inaccessible and thereby it is very difficult to search for “prior art” comprehensively with respect 
to traditional medical knowledge in the Indian context.  
 When it comes to the oral traditions, recognition of such knowledge as prior art in the US patent 
law system or even access by patent offices becomes all the more complicated. Steps have been 
taken to create Public Biodiversity Registers (PBRs) for careful and inclusive documentation of 
this kind of knowledge, but we are still a long way off from protecting this knowledge from 
biopiracy. 
 
Both in the documented and undocumented forms, Indian traditional medical knowledge are 
vulnerable to misappropriation and exploitation. 
 
How do we protect our traditional medical knowledge from biopiracy? From one point of view, 
we have two options of preventing a patent from being filed in the first place or revoking a 
wrongly granted patent in a counteractive approach.  The experience with turmeric and neem has 
taught us that we have to take preventive steps though it is possible to wage a battle to revoke 
wrongly granted patents. 
 
From another point of view we have two approaches to adopt – one is to work by adjusting with 
the existing patent laws systems and the other is to suitably modify patent laws so that we create 
a system that intrinsically protects traditional knowledge.   The present global patent laws cannot 
intrinsically protect traditional knowledge, because they were designed to exploit and not protect 
it.  
 
The Traditional Knowledge Digital Library (TKDL) is a revolutionary step taken in recent times 
to prevent misappropriation of traditional medical knowledge of India.  TKDL is essentially a 
precautionary approach and attempts to address the issues of non-recognition of traditional 
knowledge as prior art due to lack of documentation as well as its non-accessibility to 
international patent examiners all over the world. 
 
TKDL attempts to make available in a digital format traditional medical knowledge codified in 
popular Ayurvedic texts used currently and the complete set of which could be procured for a 
few thousand rupees.  The knowledge codified in these texts would be translated in a structured 
way to English and many other languages of the world so that it can be searched by international 
patent officers to rule out prior art on patent claims based on traditional medical knowledge.  
TKDL aims to facilitate access to traditional medical knowledge in patent offices which is 
already in the public domain and freely accessible to scholars and researchers alike. 
 
In principle, the TKDL does fill in the gap of making available documented traditional medical 
knowledge of India in a form that can be used by patent offices to check on prior art.  But to 
what extent can it prevent biopiracy? And ironically enough, will it facilitate biopiracy 
indirectly? 
 It appears that the TKDL can only prevent biopiracy in a limited way, given the fact that the 
knowledge it represents is only a fraction of the vast collection of published and unpublished 
manuscripts preserved in India and abroad.  Many of these manuscripts can be stealthily 
accessed by scholars in any part of the world and it is a matter of excitement and concern that 
scholarship and expertise on Indian medical manuscripts is growing in Europe and other parts of 
the world.  On the one hand, it is commendable that scholars outside our country are engaged in 
study of our traditional knowledge.  But on the other hand, development of such expertise would 
greatly facilitate bio piracy.  The tentacles of the TKDL cannot reach out to all these areas.  Any 
scholar can still read from an old manuscript preserved somewhere in the world and conjure a 
new product based on the knowledge it contains and escape the notice of the patent offices in 
spite of TKDL. 
 
The prospects of TKDL directly facilitating biopiracy seems to be a less likely possibility 
although the prospects of making available such diverse knowledge in a digital form in multiple 
languages does create an uneasy feeling in our minds.  If the patent officers actually screen the 
TKDL before accepting patent applications, then TKDL seems to have the possibility to prevent 
biopiracy in an unprecedented albeit limited way. 
 
On the other hand, TKDL might open up possibilities for better exploitation of indirectly derived 
applications of the traditional medical knowledge it makes easily available in one place.  Or will 
the creators of the TKDL and other policy makers ensure that it is made conditionally accessible 
to only authorized individuals for specified purposes.  Already, debates have surfaced on the 
prospects of sharing the TKDL with foreign multinationals and how such tie-ups could benefit 
the traditional medicine sector in India on whom these MNCs would be dependent to utilize the 
traditional knowledge in an effective way.  Fingers crossed. 
 
It does not look like TKDL can be misappropriated in an obvious way.  But one cannot be sure 
that it may not be utilized to develop not so obviously derived and skillfully modified 
applications of traditional medical knowledge that cannot be counteracted with the TKDL in its 
present form. 
 
There is an exclusive emphasis on reverse pharmacology and discovery of the so-called new 
chemical entities from traditional medical knowledge.  It is very doubtful whether this approach 
will benefit the promotion of traditional medicine or the health care priorities of a country like 
India.  In a few decades from now, we would have reduced our plant wealth into a collection of 
single molecules and reinvented the health problems that were created by the reductionistic 
approach of biomedicine.  Such an eventuality is in the asking if we join hands with MNCs for 
drug development based on traditional medical knowledge.  MNCs would only be interested in 
discovering drugs over which they can exercise control. 
 They would not be primarily interested in promoting traditional medicine.  The reverse 
pharmacology approach will be meaningful only if we create a platform for Indian scientists and 
Ayurvedic practitioners to work with India’s healthcare concerns and priorities in view. 
 
Science and scientific techniques have to be applied to traditional medical knowledge within a 
holistic perspective if traditional medicine is to make original contributions to health care issues 
globally.  Operating as it does from within the limitations of lopsided global patent laws and the 
reductionistic framework of biomedicine, the TKDL may fail to deliver the goods in the long run 
in spite of the enthusiasm and promise it generates in the short run. 
 
A matter of real concern is that India should not loose the initiative in bioprospecting in the event 
of opening up the TKDL for scientific research.  Like China, Indian scientists and Ayurvedic 
researchers should collaborate to mine traditional medical knowledge and file patents so that this 
knowledge will remain in our control. 
 
Yet another issue that needs to be addressed is benefit sharing and making sure that mechanisms 
are in place to reward the indigenous communities that have preserved this knowledge for 
centuries.  The danger of Indian versions of the MNCs exploiting a fertile situation cannot be 
ruled out altogether.  There is a limit to the adjustments that we can make within the existing 
global patent system. 
 
We need to transcend the prevailing patent system and look up to the creation of patent laws that 
can intrinsically protect traditional knowledge and also a research agenda that is sensitive to the 
holistic framework of traditional medicine. 
 
In the new patent regime, the emphasis has to be on absolute novelty.  What is being patented 
should not have pre-existence in any way, irrespective of whether it was published or not.  This 
is tantamount to countries attempting to protect traditional knowledge demanding for patent laws 
that will accord novelty only to things that have not pre-existed.  In the ultimate analysis, 
biodiversity per se, has to be accorded the status of “prior art” and only then we can be sure that 
an effective mechanism is in place to protect traditional knowledge, medical or otherwise.  
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